Merck KGaA reportedly considering generics sale

Germany's Merck KGaA is mulling the possible sale of its generics drug business, according to a news report. The unit could be worth about €4 billion and the money would help fund its acquisition of Switzerland's Serono as it focuses on developing new therapies. Any sale would likely be to financial investors, analysts note. The European drug company declined to comment on the report.

- here's the AFX report on Merck's plans

Suggested Articles

Loretta Itri, M.D. has been helping Immunomedics out with its troubled antibody-drug conjugate. Now, she’s signing on as its chief medical officer.

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda.

The fund received money from Chinese organizations inside and outside the biopharma industry, enabling CICC Capital to ease past its financing goal.